| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.5K | 9.7% |
| Total Income | 1.5K | 12.6% |
| Expenditure | 1.0K | 9.9% |
| PBT | 432.52 | 18.5% |
| Net Profit | 322.78 | 18.3% |
| OPM | 25.30% | 0.12pp |
| NPM | 21.78% | 1.53pp |
| EPS | 11.87 | 18.3% |
Colgate-Palmolive (India) Reports Q3 FY25 Net Sales Growth of 4.7% and 9.2% for Nine Months
28 Jan 2025 · 28 Jan 2025, 09:25 pm
Summary
Colgate-Palmolive (India) Ltd. announced its financial results for the third quarter and nine months of the fiscal year 2024-25. The company reported net sales of Rs. 1,452 crore for the quarter ended December 31, 2024, a growth of 4.7% year-on-year. The net sales growth for the nine months was 9.2% year-on-year at Rs. 4,547 Crore. The company's gross margin and EBITDA margin showed sequential improvement over the previous quarter, but were down from the last year’s high base. The net profit after tax for the quarter was at Rs. 322.8 crore, and for the nine months, it was at Rs. 1,081.8 Crore, a growth of 14.6% year-on-year. The company launched a tech-enabled Oral Health Movement, the largest oral health initiative in India, during the quarter.
Key Highlights
- 1
Colgate-Palmolive (India) Ltd. reported net sales growth of 4.7% for Q3 FY25 and 9.2% for the nine months ended December 31, 2024.
- 2
The company's gross margin and EBITDA margin showed sequential improvement over the previous quarter.
- 3
Net profit after tax for the quarter was at Rs. 322.8 crore, and for the nine months, it was at Rs. 1,081.8 Crore.
- 4
The company launched a tech-enabled Oral Health Movement, the largest oral health initiative in India.
Management Comments
Prabha Narasimhan
This has been a quarter of relatively soft demand, particularly in the urban market. In these market conditions and a heightened competitive landscape, we delivered a resilient performance this quarter with Toothpaste reporting mid-single digit intrinsic volume growth and continued competitive growth on toothbrushes. We continue to see positive momentum in our premium portfolio, driven by science-backed innovations. Margin profile continues to remain healthy. While the near term macro environment continues to look challenging, we are committed to driving growth through focus on a strategy that is working.
Informational and educational content only. Not investment advice.